Karman Space & Defense at Morgan Stanley conference: growth, scale and cash

Karman Space & Defense reiterated approximately 25% annual organic growth through the end of the decade, EBITDA margins near 30%, and positive cash flow in 2H 2026. Backlog rose more than 80% in the latest quarter and book-to-bill reached 1.6x over the past 18 months, supported by missile replenishment, unmanned systems, and space-launch demand. The company is expanding capacity, including a 200,000-square-foot Salt Lake City facility expected to provide roughly 4x current production capacity for certain unmanned-system launch products, while pursuing three additional missile long-term agreements. Despite these fundamentals, KRMN traded at $37.12, down 64% from its $118.38 52-week high, with management aiming to improve transparency, working-capital conversion, and cash-flow guidance.

Analysis

KRMN’s equity problem is not demand but credibility of conversion: investors are discounting an acquisition-led defense roll-up with a large working-capital requirement rather than capitalizing a 25% organic compounder. The next re-rating depends on independently observable evidence—quarterly organic-growth disclosure, contract-asset reduction, and second-half free-cash-flow delivery—not management’s terminal-margin assertions. If these validate, the stock can migrate from a “story-stock” multiple toward established high-growth defense suppliers; if not, its nominal backlog will not protect the multiple.

Capacity is the key second-order constraint. New facilities create a 12-24 month execution window in which underutilization, labor ramp, qualification delays, or supplier bottlenecks can absorb the expected operating leverage; meanwhile, primes such as LMT and LHX retain purchasing leverage because KRMN’s strategic value rises only once capacity is qualified and interchangeable supply is limited. Multi-year agreements could reduce factory volatility and fund capex through advances, but they also crystallize delivery, escalation, and schedule risk before the company has demonstrated sustained cash conversion.

Contrarian view: the magnitude of the drawdown may be pricing a financing or integration failure rather than merely skepticism toward growth. That creates asymmetric upside only if the next two reporting periods establish that acquisition accounting is not masking organic demand and that cash generation improves without cutting capex. The more likely near-term catalyst is de-risking through disclosure, not a step-change in defense spending; European expansion is strategically additive but introduces export-control, integration, and local-content friction before it contributes meaningfully.

The clean relative expression is KRMN versus mature primes rather than an outright defense-sector beta bet. LMT/LHX have lower execution risk and larger funding visibility, so a KRMN recovery requires company-specific proof; absent that proof, continued multiple compression can persist despite favorable end markets.

Key Decisions for Investors

• Initiate a small, staged long KRMN only after the next earnings release confirms positive free cash flow and reports organic growth at or above 20%; add if contract-asset days continue to decline. Target a 6-12 month re-rating toward $55-$65, with a hard thesis stop on renewed negative cash flow or organic growth below 15%.
• For event risk, use a 6-9 month KRMN call spread rather than unhedged equity—for example, buy the $40 call/sell the $60 call if liquidity permits. This isolates a transparency/cash-conversion catalyst while capping exposure to another execution-driven drawdown.
• Until cash conversion is demonstrated, maintain a relative hedge: long LHX or LMT against any KRMN long. Reduce the hedge only after two consecutive quarters of positive cash generation and no material EBITDA-margin erosion; the pair protects against broad defense-budget or rates-driven multiple compression.
• Monitor the three pending missile agreements as an alert, not a buy trigger. Upgrade conviction only if disclosed minimum volumes, customer advances, escalation terms, and incremental capex imply cash-neutral capacity expansion; a large backlog increase without advances would worsen the balance-sheet and working-capital debate.
• Avoid extrapolating European M&A into 2027 estimates until Walker closes cleanly and export-control/ERP integration is complete. Any delay, remediation cost, or margin dilution would undermine the central claim that acquisitions are immediately accretive.